NovaQuest Capital Management

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative and life-altering therapies that address critical unmet medical needs in areas such as transplantation, autoimmune diseases, gene therapy, and oncology. Hansa Biopharma employs a proprietary antibody-cleaving enzyme technology platform to target disease-causing antibodies. Its lead product candidate, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is being explored for potential applications in other organ transplants and acute autoimmune conditions. The company operates primarily in Sweden, other European countries, and the United States, generating most of its revenue from product sales.

Lexitas Pharma Services is a full-service clinical research organization (CRO) focused on supporting pharmaceutical and biotechnology companies in the management of ophthalmic clinical trials. The company provides a comprehensive range of services, including clinical operations, study design, content development, monitoring, medical oversight, and site relations. By leveraging its expertise, Lexitas Pharma facilitates the efficient execution of various phases of clinical trials, thereby enabling its clients to advance their ophthalmic research and development initiatives.

TARGAN is a bio-systems company dedicated to enhancing animal health and productivity in the poultry, livestock, and aquaculture sectors. It is developing an innovative vaccination system that aims to replace traditional mass spray methods with a more precise approach, ensuring that every newly hatched chick receives the appropriate vaccine. This technology not only aims to improve immunization rates but also enhances the natural immune response to diseases, leading to better overall flock health. By increasing vaccination accuracy and consistency, TARGAN's solution helps reduce reliance on antibiotics, contributing to cleaner and healthier livestock. The company's focus on improving animal well-being and operational efficiency positions it as a leader in the field of animal production.

Covenant Animal Health Partners focuses on the development and registration of revenue-ready animal health products. The company aims to meet critical market needs for both production and companion animals by advancing new assets into the portfolios of industry partners. By providing innovative solutions, Covenant assists animal health manufacturers and distributors in enhancing their product offerings.

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company specializing in medical dermatology therapeutics. The company's lead product candidate, Tapinarof, is a topical cream undergoing Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Dermavant's pipeline includes additional candidates in various stages of development, such as Cerdulatinib, which targets vitiligo and other inflammatory skin conditions, and Oxybutynin/Pilocarpine, an oral therapy for primary focal hyperhidrosis. Preclinical candidates include DMVT-503, aimed at treating acne vulgaris, and DMVT-501, a potential treatment for atopic dermatitis. Dermavant Sciences has established licensing agreements with several pharmaceutical companies and operates as a subsidiary of Roivant Sciences Ltd. The company, originally known as Roivant Dermatology Ltd., rebranded in June 2016 and is based in London, United Kingdom.

Argenta is a contract research organization (CRO) and contract manufacturing organization (CMO) that specializes in the animal health sector. The company offers a range of services, including pre-clinical development and the manufacturing of veterinary products such as solid dose tablets, topical liquids, sterile injectables, and oral liquids. Argenta operates contract manufacturing facilities in New Zealand, the United Kingdom, and the United States, enabling it to provide comprehensive product development services to clients globally, regardless of scale. Through its expertise, Argenta supports the advancement of animal health products from initial development to market readiness.

Aceragen is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for rare and ultra-rare diseases, including oncology. The company is dedicated to addressing unmet medical needs by developing treatments grounded in well-established biological principles and advanced therapeutic concepts. With a focus on late-stage programs, Aceragen aims to provide effective solutions for individuals suffering from these challenging conditions.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Pro-ficiency is a company that specializes in providing tech-enabled training and compliance solutions specifically designed for clinical trials. It offers a comprehensive suite of services that includes turnkey virtual training simulators and tools for monitoring training and compliance. The company's platform supports clinical trial investigators and site staff by delivering virtual simulation training and human resources compliance services. Additionally, Pro-ficiency creates original content and utilizes predictive analytics to provide real-time data to sponsors, aiding in the identification and mitigation of potential study errors and protocol violations. By streamlining training and compliance processes, Pro-ficiency aims to reduce the time, cost, and risk associated with clinical trials.

CoreRx, Inc. is a contract development manufacturing organization (CDMO) based in Clearwater, Florida, that specializes in providing comprehensive services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms for pharmaceutical and biotechnology companies. Founded in 2006, CoreRx offers a wide array of pre-formulation services, including physical and chemical characterization, stability evaluations, and formulation development for various medication forms such as tablets, capsules, gels, creams, and powders. The organization is equipped with extensive instrumentation and adheres to rigorous quality systems to ensure timely and efficient results. By delivering complete cGMP solutions, CoreRx enables clients to streamline their development processes, thereby maximizing investments and reducing overall costs.

Mileutis LTD is a biopharmaceutical company based in Ness Ziona, Israel, founded in 2004. It specializes in the discovery, development, and commercialization of biologically sourced therapies aimed at improving both animal and human health. The company offers products such as Imilac, an intramammary solution designed for use at the beginning of the dry period to manage mastitis and enhance milk production, and Milac, which treats intramammary infections during lactation. Mileutis focuses on developing natural and novel peptides, which hold significant potential for addressing chronic and infectious diseases while reducing the reliance on antibiotics in both veterinary and human medicine. Its innovations also enhance veterinary dairy management by increasing productivity, thereby benefiting overall health management strategies.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

InformedDNA specializes in genetics benefits management services, aiming to enhance healthcare spending and patient care through expert genomic insights. The company provides a robust platform that connects genetic counselors with patients, focusing on policy development, prior authorization for genetic testing, and payment integrity claims edits. InformedDNA offers utilization analytics and lab network strategies, empowering genetics experts to guide both patients and clinicians in effectively utilizing genetic information and novel gene-based treatments. With the largest independent team of board-certified genetics specialists in the United States, the company combines extensive clinical experience with advanced technology to deliver tailored solutions. InformedDNA is committed to optimizing clinical decisions, managing downstream costs, and improving health outcomes, ensuring that patients receive the highest quality of care through informed decision-making.

Nevakar Inc. is a pharmaceutical company based in Bridgewater, New Jersey, specializing in the development of innovative ophthalmic and injectable products. Founded in 2015, the company aims to create enhanced formulations of existing FDA-approved molecules to meet unmet clinical and commercial needs. Nevakar's efforts are underpinned by a robust research and development infrastructure situated in the New Jersey Center of Excellence, complemented by a seasoned management and leadership team. Through intensive R&D and clinical initiatives, Nevakar is committed to advancing healthcare solutions in its specialized fields.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Catalyst Clinical Research, LLC is a contract research organization based in Durham, North Carolina, specializing in providing staffing services and clinical operation solutions to biotechnology, pharmaceutical, and medical device companies. Established in 2013, the company leverages over two decades of industry experience to support clinical development programs with therapeutically-aligned professionals and customized solutions. Catalyst focuses on oncology and offers a range of clinical trial services, including multi-therapeutic resourcing and functional solutions. By simplifying clinical research data, the organization aims to accelerate critical trial decisions, particularly in early-phase studies, thereby facilitating the development of next-generation cancer therapies for patients.

Mesoblast Limited is a biopharmaceutical company specializing in the development and commercialization of allogeneic cellular medicines for a variety of complex diseases. Utilizing its proprietary Mesenchymal Precursor Cell (MPC) technology, the company addresses conditions resistant to conventional treatments, particularly those involving inflammation. Mesoblast's product pipeline includes MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain due to degenerative disc disease, among others. The company is also advancing MPC-300-IV, which targets biologic refractory rheumatoid arthritis and diabetic kidney diseases in Phase II clinical trials. Headquartered in Melbourne, Australia, Mesoblast operates in multiple countries, including the United States, and has formed strategic partnerships with various pharmaceutical companies to enhance its product offerings and expand its market reach. Founded in 2004, Mesoblast aims to provide innovative therapies in fields such as oncology, hematology, and orthopedic disorders.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions designed to streamline clinical research for sites, sponsors, contract research organizations (CROs), and patients. Founded in 2006 and headquartered in Horsham, Pennsylvania, with additional offices in Winston-Salem and Cary, North Carolina, Philadelphia, Pennsylvania, and Cambridge, Massachusetts, the company offers a suite of innovative tools including SureSource, an electronic source platform that captures data and documents at the site level, and Lunexis ePRO+, which facilitates patient participation in studies. Additionally, Clinical Ink provides CentrosHealth, a patient engagement platform that includes configurable apps to enhance patient involvement and compliance throughout clinical trials. The company aims to improve clinical trial workflows by integrating electronic data capture and reducing manual processes, ensuring that clients have access to high-quality, validated data.

Azurity Pharmaceuticals is a pharmaceutical company dedicated to developing and marketing drug products that cater to patients with unmet medical needs. The company focuses on creating innovative medicines for various conditions, including attention deficit hyperactivity disorder (ADHD), hypertension, and congestive heart failure. A significant emphasis is placed on developing and commercializing oral liquid medications, which are particularly beneficial for children, elderly patients, and others who may struggle to swallow pills or tablets. In addition to these areas, Azurity also produces medications like antimicrobial agents and mouthwashes, enhancing the ability of pharmacists to provide better alternatives to traditionally compounded medications.

Viamet Pharmaceuticals specializes in the discovery and development of novel therapeutic agents targeting metalloenzymes through its proprietary Metallophile™ Technology. This innovative approach leverages the company’s expertise in bioinorganic chemistry to develop inhibitors that demonstrate significant therapeutic and commercial potential. Viamet focuses on creating best-in-class analogs of existing metalloenzyme inhibitors, which allows for the rapid and cost-effective generation of patentable small molecule compounds. The company’s therapeutic pipeline addresses critical health challenges, including invasive fungal infections, cancer, cardiovascular conditions, and orphan diseases, by targeting the body's ability to utilize essential metal ions such as zinc and iron.

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health and endocrine diseases. Its lead product, relugolix, is an oral, once-daily gonadotropin-releasing hormone receptor antagonist designed to treat heavy menstrual bleeding associated with uterine fibroids, endometriosis-related pain, and advanced prostate cancer. The company is also advancing MVT-602, an oligopeptide kisspeptin agonist that has completed a Phase 2a study aimed at addressing female infertility in assisted reproduction. Myovant Sciences was established in 2016 and is headquartered in Brisbane, California. It collaborates with Pfizer to develop and commercialize relugolix across oncology and women's health.

California Cryobank, Inc. is a reproductive tissue bank that specializes in providing a range of services, including frozen donor sperm, egg services, and reproductive tissue storage. Founded in 1977 and based in Los Angeles, California, the company operates branch laboratories in multiple locations across the United States, including Palo Alto, Westwood, Cambridge, New York, and Houston. California Cryobank also offers private semen cryopreservation, artificial insemination guidance, donor matching, genetic services, and andrology services. In addition, it provides cord blood and tissue banking through its subsidiary, FamilyCord. The company is registered with the FDA and holds accreditations from the AATB and AABB, as well as licenses from California and New York. California Cryobank serves clients not only in the United States but also in Europe, South America, and Asia.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

BioCritica is a biotechnology company dedicated to addressing critical care needs in the hospital market, particularly focusing on severe sepsis treatment with its product, Xigris. The company is actively developing a pipeline of additional products aimed at enhancing patient outcomes and supporting clinicians. BioCritica's mission centers on creating and commercializing innovative solutions that significantly improve the quality of life for patients facing critical health challenges.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Protemix is a biopharmaceutical company that discovers, develops, and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes, and other metabolic disorders. The company was founded in 1999 and is based in Auckland, New Zealand with an additional office in San Diego, California.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Sirion Therapeutics is a biopharmaceutical company, engaged in developing, and commercializing of products for the protection of eyesight.